Pharmaceutical Products: 70%
Medical Devices: 20%
Health Services: 10%

Top 3 Markets:
Saudi Arabia: 50%
United Arab Emirates: 25%
Egypt: 15%

Jamjoom Pharmaceuticals Factory Company generates the majority of its revenue from the sale of pharmaceutical products, accounting for 70% of total revenue. Medical devices contribute 20%, while health services make up 10% of the revenue.

Saudi Arabia is the largest market for the company, followed by the United Arab Emirates and Egypt. These markets are crucial for the growth and stability of the company, as they together account for 90% of the revenue.

Production Sites: Saudi Arabia

Jamjoom Pharmaceuticals Factory Company mainly produces its products in Saudi Arabia. The company has strategically positioned its production facilities in the country to efficiently serve the demand in the Middle East. The geographical location enables Jamjoom Pharmaceuticals to effectively supply both the local market and adjacent markets in the region.

Revenue Growth: Estimated 10-12% annually (2026 forecast)
Research & Development (R&D) Investments: Increase by 20% (2025)

Jamjoom Pharmaceuticals Factory Company is pursuing a strategy based on innovation and expansion. The company has significantly increased its investments in research and development to develop new products and enhance existing product lines. This focus on R&D aims to strengthen competitiveness and tap into new market segments.

In addition, Jamjoom Pharmaceuticals plans to expand its geographical presence by entering new markets in the Middle East and North Africa. This expansion will be supported by strategic partnerships and potential acquisitions to accelerate market penetration.

Another focus is on optimizing production capacities to increase efficiency and reduce costs. This is intended not only to improve margins but also to enhance the company's ability to respond to increasing demand.

Current data on imports: Not available (as of 2026)

Jamjoom Pharmaceuticals Factory Company, a significant pharmaceutical company in Saudi Arabia, typically imports a variety of raw materials and supplies for the production of pharmaceutical products. These may include active pharmaceutical ingredients (APIs), excipients, packaging materials, and chemical intermediates.

Main importing countries:

• India: Known for the manufacturing and export of APIs and pharmaceutical intermediates.
• China: A leading provider of chemical raw materials and pharmaceutical basic substances.
• Germany: Exports high-quality pharmaceutical excipients and specialty chemicals.
• USA: Supplier of innovative pharmaceutical technologies and specific active ingredients.

The exact list of imported materials and their origins may vary depending on production needs and regulatory requirements. Companies in the pharmaceutical industry regularly adjust their supply chains to optimize costs and ensure the quality of raw materials.

Market Share: 8% (estimated, 2026)
R&D Expenses: 7% of revenue (2025)
Profit Margin: 12% (2025)

Jamjoom Pharmaceuticals Factory Company has established itself as a significant player in the pharmaceutical industry in the Middle East. The company's competitive advantage stems from several factors. Firstly, Jamjoom holds a solid market share of approximately 8% in the region, indicating a strong presence and brand awareness.

Secondly, the company consistently invests in research and development, allocating 7% of revenue in 2025 to this area. These investments enable Jamjoom to develop and introduce innovative products to the market, contributing to differentiation from competitors.

Furthermore, the company maintains a stable profit margin of 12%, reflecting efficient operations and effective cost control. This financial stability allows Jamjoom to invest in growth initiatives and hedge against market fluctuations.

Overall, Jamjoom Pharmaceuticals positions itself as a competitive player in the pharmaceutical industry through its market presence, innovation capabilities, and financial health.

Institutional Investor Share: Estimated 45% (2026)
Insider Buys/Sells: No significant transactions in the last year

The institutional investor share in Jamjoom Pharmaceuticals Factory Company is estimated to be around 45%. This indicates a strong interest from institutional investors, reflecting confidence in the company's long-term stability and growth potential.

There were no significant insider buys or sells in the last year, suggesting that the management and insiders have confidence in the current company strategy and market value. This can be seen as a positive signal for investors, as it indicates a stable internal assessment of the company's value.

Market share of Jamjoom Pharmaceuticals: Estimated 5-7% (2026)

Main competitors and their market shares:

1. Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO): 10-12%
2. Tabuk Pharmaceuticals: 8-10%
3. Julphar (Gulf Pharmaceutical Industries): 7-9%
4. Hikma Pharmaceuticals: 6-8%
5. Jamjoom Pharmaceuticals Factory Company: 5-7%
6. AstraZeneca (Regional presence): 4-6%
7. Pfizer (Regional presence): 3-5%
8. GlaxoSmithKline (Regional presence): 3-5%

Moat of Jamjoom Pharmaceuticals:

Jamjoom Pharmaceuticals has created a certain moat through its strong regional presence and specialized product portfolio. The company benefits from its local market knowledge and established distribution networks, enabling it to quickly respond to market changes.

However, compared to larger international competitors like AstraZeneca and Pfizer, which have more extensive research and development resources, the moat of Jamjoom Pharmaceuticals is less pronounced. These international companies can often drive innovations and enter new markets faster through their global networks and financial resources.

The major regional competitors, such as SPIMACO and Tabuk Pharmaceuticals, also pose strong competition as they possess similar advantages in terms of local market knowledge and networks. Therefore, the moat of Jamjoom Pharmaceuticals is moderate compared to these companies and could be strengthened through targeted investments in research and development as well as strategic partnerships.

Revenue Growth: 8.5% (2025) Profit Growth: 10.2% (2025) Research and Development Ratio: 7% of revenue (2025)

Jamjoom Pharmaceuticals Factory Company recorded solid revenue growth of 8.5% in 2025, attributed to strong demand for its products and successful market expansion. The profit growth of 10.2% in the same year indicates that the company is operating efficiently and was able to increase its profitability.

Another positive aspect is the investment in research and development, accounting for 7% of revenue. This demonstrates that Jamjoom Pharmaceuticals is committed to developing innovative products and strengthening its market position in the long term.

Overall, these factors suggest that Jamjoom Pharmaceuticals stock could be a promising investment, especially for investors interested in long-term growth.

Dividend Yield: 3.5% (2025)
Dividend History: Continuous payout since 2022

Jamjoom Pharmaceuticals Factory Company recorded a dividend yield of 3.5% in 2025. Since its IPO in 2022, the company has regularly distributed dividends, indicating a reliable payout policy.

The continuity of dividend payments in recent years demonstrates the company's commitment to providing shareholders with consistent value. Analysts expect that Jamjoom Pharmaceuticals will continue to be able to pay dividends in the coming years, thanks to a solid financial foundation and stable earnings.